<DOC>
	<DOCNO>NCT01222026</DOCNO>
	<brief_summary>Patients primary hyperparathyroidism ( pHPT ) osteopenia osteoporosis treat strontium ranelate/Ca+Vitamin-D placebo/Ca+Vitamin D successful surgical treatment pHPT . Strontium ranelate/Ca + Vitamin-D help regain bone mass patient osteopenia osteoporosis successful parathyroidectomy pHPT result higher gain BMD placebo treat patient .</brief_summary>
	<brief_title>Systematic Treatment After Successful Surgical Treatment Primary Hyperparathyroidism With Strontium Ranelate</brief_title>
	<detailed_description>The chronic excessive hypersecretion parathyroid hormone ( PTH ) significant impact bone remodel . In primary hyperparathyroidism ( PHPT ) bone turnover increase , result high resorption bone thus loss bone density . After successful surgical treatment pHPT bone metabolism switch catabolic state anabolic state . However study show especially postmenopausal woman regain significantly less BMD woman suffer osteopenia osteoporosis often would need regain much bone mass possible prevent fracture . The optimal state would reach normal BMD . Although state hardly reachable especially patient may benefit treatment act anti-resorptive rise bone formation . The drug combine quality know far Strontium ranelate . Therefore hypothesis Strontium ranelate/Ca + Vitamin-D help regain bone mass patient osteopenia osteoporosis successful parathyroidectomy pHPT result higher gain BMD placebo treat patient .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Hyperparathyroidism , Primary</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Strontium ranelate</mesh_term>
	<criteria>biochemically proven PHPT , PTX plan osteopenia ( tscore &lt; 1 &gt; 2.5 ) osteoporosis ( tscore â‰¤ 2.5 ) accord WHO Criteria [ 27 ] Premenopausal woman Cancer ( lung , breast , prostatic , parathyroid cancer thyroid carcinoma &gt; 1cm ) Persisting recurrent PHPT ( postoperative hypercalcemia ) Fourgland hyperplasia Multiple endocrine neoplasia ( MEN ) hereditary PHPT Familial hypocalciuric hypercalcaemia ( Ca/creatinine ratio &lt; 0.01 ) Anamnestic pulmonal embolism deep venous thrombosis Blood coagulation disorder coagulopathy Phenylketonuria Renal impairment ( creatinine clearance &lt; 30ml/h ) Severe hepatic disorder Severe systemic disorder Thyroid dysfunction Immobilisation Intake drug potential effect BMD like glucocorticoid , lithium , estrogenreplacement therapy , selective Estrogenreceptor modulators ( sERMs ) , bisphosphonates last three month Known allergy component study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Primary Hyperparathyroidism</keyword>
	<keyword>Osteopenia</keyword>
	<keyword>Osteoporosis</keyword>
</DOC>